Tag: Drug
Analytical Strategies for Drug Development Seminar in Cambridge
Morton Grove, IL (PRWEB) May 28, 2015 Regis Technologies will host a technical talk in Cambridge, MA delivered by their Director of Analytical Method Development, Paul Wrezel, Ph.D. The talk is free and open to the public. Arrive at 8:00am for coffee and networking; the seminar will begin at 8:30am and will last one hour. […]
Keynotes Announced for PODD: Partnership Opportunities in Drug Delivery Event
New York, New York (PRWEB) June 10, 2015 The Conference Forum is delighted to announce its top-tier industry keynote speakers for the 5th annual Partnership Opportunities in Drug Delivery (PODD) event to be held Oct. 5 – 6 at the InterContinental Boston. The two-day event will be kicked-off by serial entrepreneur and renowned chemical […]
Technological Advancements Driving the Drug Discovery Technologies Market; Emerging Markets to Reach $23.6 Billion in 2019
(PRWEB) April 02, 2015 Wellesley, Mass., April 2, 2015 – BCC Research (http://www.bccresearch.com) reveals in its new report on drug discovery technologies that notable advances in technology have been influencing all aspects of drug discovery and development in the past three decades. These include identification of areas for research through increasing the value of new […]
New Research Finds Immunotherapy Drug May Fight Mesothelioma Better at Higher Doses, According to Surviving Mesothelioma
Raleigh, NC (PRWEB) April 01, 2015 Doctors in Italy have just published research suggesting that the immunotherapy drug tremelimumab is more effective against mesothelioma at higher doses. Surviving Mesothelioma has just posted more on the research on its website. Click here to read it now. The new study involved 29 patients at the University […]
Orphan Drug Approval May Mean New Treatment Option for Mesothelioma, According to Surviving Mesothelioma
Raleigh, NC (PRWEB) April 01, 2015 Patients with inoperable mesothelioma may soon have a new treatment option available to them, thanks to the FDA’s approval of CRS-207’s orphan drug application . Click here to read the full story on the Surviving Mesothelioma website. CRS-207 is an immunotherapy vaccine made from a modified version of […]